CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
Cancer immunology, immunotherapy : CII
View this publicationCancer immunology, immunotherapy : CII
View this publicationMolecular cell
View this publicationHead & face medicine
View this publicationHamostaseologie
View this publicationHamostaseologie
View this publicationCancer immunology, immunotherapy : CII
View this publicationCellular and molecular gastroenterology and hepatology
View this publicationPLoS neglected tropical diseases
View this publicationTuberculosis (Edinburgh, Scotland)
View this publicationFrontiers in cardiovascular medicine
View this publication